Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nilofer Azad

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Cancer Metastasis Reviews|September 30, 2021
Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistanceThatcher Heumann, Nilofer Azad
Cancer Biology & Therapy|August 17, 2012
Reporting of preclinical tumor-graft cancer therapeutic studiesElizabeth Sugar, Adam J Pascoe, Nilofer Azad
Journal of Gastroenterology and Hepatology|June 10, 2014
Racial disparities and colorectal cancer survival in older adults with and without diabetes mellitusSalman Waheed, Nilofer Azad, Sehrish Waheed, et al.
Oncotarget|October 11, 2024
A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapyMurtaza Ahmed, Brent K Larson, Arsen Osipov, et al.
Nature Reviews. Clinical Oncology|April 3, 2013
The future of epigenetic therapy in solid tumours--lessons from the pastNilofer Azad, Cynthia A Zahnow, Charles M Rudin, et al.
Disease Markers|December 7, 2007
Proteomics as a tool for biomarker discoveryElise C Kohn, Nilofer Azad, Christina Annunziata, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 26, 2026
Liver-Directed Therapy for Colorectal Cancer: Where Are We Now?Yi Song, Meenakshi Jeeva, Robert P Liddell, et al.
Epigenetics|December 6, 2016
GPX3 promoter methylation predicts platinum sensitivity in colorectal cancerLorraine Pelosof, Sashidhar Yerram, Todd Armstrong, et al.
Molecular Cancer Therapeutics|May 2, 2015
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft ModelsChaoxin Hu, Tikva Dadon, Venugopal Chenna, et al.
Cancer Immunology Research|August 14, 2021
Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist TherapyLauren Dennison, Amanda Ruggieri, Aditya Mohan, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Cancer Metastasis Reviews|September 30, 2021
Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistanceThatcher Heumann, Nilofer Azad
Cancer Biology & Therapy|August 17, 2012
Reporting of preclinical tumor-graft cancer therapeutic studiesElizabeth Sugar, Adam J Pascoe, Nilofer Azad
Journal of Gastroenterology and Hepatology|June 10, 2014
Racial disparities and colorectal cancer survival in older adults with and without diabetes mellitusSalman Waheed, Nilofer Azad, Sehrish Waheed, et al.
Oncotarget|October 11, 2024
A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapyMurtaza Ahmed, Brent K Larson, Arsen Osipov, et al.
Nature Reviews. Clinical Oncology|April 3, 2013
The future of epigenetic therapy in solid tumours--lessons from the pastNilofer Azad, Cynthia A Zahnow, Charles M Rudin, et al.
Disease Markers|December 7, 2007
Proteomics as a tool for biomarker discoveryElise C Kohn, Nilofer Azad, Christina Annunziata, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 26, 2026
Liver-Directed Therapy for Colorectal Cancer: Where Are We Now?Yi Song, Meenakshi Jeeva, Robert P Liddell, et al.
Epigenetics|December 6, 2016
GPX3 promoter methylation predicts platinum sensitivity in colorectal cancerLorraine Pelosof, Sashidhar Yerram, Todd Armstrong, et al.
Molecular Cancer Therapeutics|May 2, 2015
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft ModelsChaoxin Hu, Tikva Dadon, Venugopal Chenna, et al.
Cancer Immunology Research|August 14, 2021
Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist TherapyLauren Dennison, Amanda Ruggieri, Aditya Mohan, et al.
Pageof 5